Development of a CRISPR-based diagnostic tool for rapid detection of antimicrobial resistance genes in clinical isolates.

Project Abstract

The rapid and accurate detection of antimicrobial resistance (AMR) determinants in clinical isolates remains a critical bottleneck in patient management and infection control. This study reports the development and validation of a CRISPR-based diagnostic platform capable of deploying sequence-specific detection of key AMR genes directly from diverse clinical specimen matrices. We designed a modular CRISPR-Cas system combining high-fidelity Cas12a nucleases with guide RNAs targeting prevalent resistance determinants spanning beta-lactamase (CTX-M, SHV, KPC, NDM, OXA-type), aminoglycoside-modifying enzymes (aac(6')-Ib, armA), and fluoroquinolone resistance determinants (qnr,aac(6')-Ib-cr, gyrA mutations). A parallel amplification strategy employing recombinase polymerase amplification (RPA) was integrated to achieve rapid, isothermal sample processing within 30–40 minutes. The assay leverages a trans-cleavage reporter that yields a fluorescence readout, enabling quantitative signal generation alongside a lateral-flow readout for point-of-care applicability. Analytical characterization demonstrated limits of detection in the low femtomolar range for purified DNA and robust performance in spiked complex matrices including whole blood, sputum, and urine, with essential performance metrics—sensitivity, specificity, positive predictive value, and negative predictive value—comparable to centralized sequencing workflows. We conducted a rigorous in silico and empirical evaluation across a panel of 500 clinical isolates collected from tertiary-care centers, confirming broad coverage of circulating AMR gene variants and minimal cross-reactivity with non-target sequences. Importantly, the platform demonstrated rapid turnaround times suitable for urgent clinical decision-making, enabling targeted antimicrobial therapy guidance and timely isolation measures to reduce nosocomial transmission. We optimized reaction conditions to minimize non-specific signals and evaluated the stability of CRISPR components under clinical storage conditions, establishing a feasible deployment blueprint for hospital laboratories and field clinics. A comparative cost-analysis indicated substantial reductions in per-test cost and turnaround time relative to conventional culture-based susceptibility testing and whole-genome sequencing, particularly when integrated into a multiplexed assay framework. This work also addresses biosafety considerations, detailing containment strategies for handling pathogenic samples and secure data management for genetic resistance determinants. In addition to the rapid diagnostic capability, the platform offers potential for resistance trend surveillance by aggregating anonymized test results to monitor emergent AMR genes in real time. The study outlines steps for regulatory approval pathways, roadmap for integration with existing laboratory information systems, and avenues for future enhancement, including expansion to metagenomic contexts and the incorporation of predictive resistance modeling. Overall, the CRISPR-based diagnostic tool demonstrates a transformative approach to AMR detection that combines speed, accuracy, and adaptability, with significant implications for patient outcomes, antimicrobial stewardship, and infection control in diverse healthcare settings.

Project Overview

What This Project Is About

---

A plain-language overview of the topic and what the project investigates.

---

---

The Problem It Addresses

---

What problem or gap this project tackles and why it matters to the field or society.

---

---

Objectives of the Project

---

1. Identify key antimicrobial resistance (AMR) genes commonly found in clinical isolates.
2. Develop a CRISPR-based assay to detect selected AMR genes rapidly and accurately.
3. Evaluate the assay's sensitivity, specificity, and time-to-result using real samples.
4. Compare the new tool with standard diagnostic methods to assess benefits and limitations.
5. Discuss practical considerations for potential clinical use and deployment.

---

---

What You Will Do Step by Step

---

1. Review background literature on CRISPR diagnostics and AMR genes.
2. Design CRISPR guide RNAs targeting chosen resistance genes.
3. Develop and optimize a detection workflow (sample prep, amplification, readout).
4. Test the assay with bacterial isolates carrying the target genes.
5. Assess performance metrics (sensitivity, specificity, speed).
6. Analyze data and compare with conventional methods.
7. Document methods, results, and potential clinical implications.
8. Prepare a concise report and present findings.

---

---

Expected Outcome

A rapid, field-friendly diagnostic tool capable of detecting key AMR genes with clear performance metrics and demonstrated potential for integration into clinical workflows.